Research programme: antisense RNA therapeutics - Ionis Pharmaceuticals
Latest Information Update: 11 Mar 2024
At a glance
- Originator Ionis Pharmaceuticals
- Class Antisense RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified